CASE REPORT article
Front. Oncol.
Sec. Gastrointestinal Cancers: Colorectal Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1567760
Salvage treatment of a metastatic colorectal cancer with pMMR/MSS in a 21-year-old male : a case report
Provisionally accepted
- 1Department of Medical Oncology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China., Beijing, China
- 2Department of Pathology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
In metastatic colorectal cancer (mCRC) patients with proficient mismatch repair (pMMR)/ microsatellite stability (MSS), beyond third-line therapies were extremely limited. Here, we reported a case of a 21-year-old male with pMMR/MSS mCRC who failed to response to both first and second-line treatment and subsequently received non-standard third-line therapy at a local hospital.This patient was referred to our hospital and we initiated salvage therapies. The fourth-line treatment including tislelizumab, regorafenib, pemetrexed, and raltitrexed was administered with a progressionfree survival (PFS) of 13 months. Then, this patient received fifth-line treatment with chidamide, fruquintinib, toripalimab, raltitrexed, and nanoparticle albumin-bound paclitaxel with a PFS of 8 months. During the whole treatment, side effects were tolerable and significantly alleviated with appropriate symptomatic therapies. In addition, cystoscopy plus transurethral resection of metastatic bladder tumor was successfully conducted to halt the bleeding. The sixth-line regimen was started and he is still under follow-up. Collectively, this patient achieved long-term survival with a high quality of life through therapies beyond third-line.
Keywords: colorectal cancer, proficient mismatch repair/microsatellite stability, PD-1 inhibitor, Chidamide, Treatment
Received: 28 Jan 2025; Accepted: 28 Jul 2025.
Copyright: © 2025 Li, Liu and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zhuo Yu, Department of Medical Oncology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China., Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.